Special Issue "Respiratory and Nasal Drug Delivery"
A special issue of Pharmaceutics (ISSN 1999-4923).
Deadline for manuscript submissions: 20 December 2013
Dr. Remigius U. Agu
Biopharmaceutics and Drug Delivery Laboratory, Dalhousie University, Halifax NS, Canada
Interests: respiratory/nasal; transporters; toxicity screening; drug delivery
Novel developments in the fields of Biotechnology and Combinatorial Chemistry rekindled overall interest in exploring the respiratory and nasal routes for systemic delivery of biomolecules (e.g., proteins, peptides and nucleic acids). Pursuits in these areas of drug delivery are not limited to macromolecules and systemic delivery. Many research groups are consistently looking for more effective ways to deliver small molecules local to the lung, nasal sinuses and brain via the nasal route. Novel approaches for efficient systemic and local drug delivery have been developed over the past few years. Such strategies include novel formulations (micro/nano particles, stent) and delivery devices. Successful respiratory and nasal drug delivery also requires sound experimental methods/model development. This special issue entitled: "Respiratory and Nasal Drug Delivery" will deal with key aspects of modern respiratory and nasal delivery. Micro-/nano-particulate delivery; formulation/delivery of aerosols and dry powders; optimization of nasal and respiratory drug absorption using in vitro, ex vivo and in situ tissue culture and animal models; brain targeting via the nasal route; exploration of mechanisms of epithelial drug permeation (e.g., active transport mechanisms); aerosol delivery simulation and other particle projectile studies; toxicological aspects of nasal and respiratory drug delivery, especially micro and nanoparticles; pharmacodynamics and pharmacokinetics of novel formulations following nasal and inhalational administration will be covered. Other relevant topics including muco-/bio-adhesive delivery, cilio-toxicity screening, delivery devices development, optimization and validation are also welcomed.
Dr. Remigius U. Agu
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- drug delivery
- drug targeting
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of Paper: Review
Title: The Current Progress in the Development of DNA Vaccine for Intranasal Administration
Author: Jenny Lam
Abstract: Intranasal delivery of DNA vaccines has become a popular research area recently. It offers some distinguished advantages over oral or parenteral route of vaccine administration, Nasal mucosal as site of vaccine administration can stimulate respiratory mucosal immunity by interacting with the nasal-associated lymphoid tissues. Different kinds of DNA vaccines are investigated to provide protection against influenza, tuberculosis, respiratory syncytial virus (RSV) and cancer /etc./. DNA vaccines have some attractive development potential, like producing cross-protection towards different influenza subtypes, enabling the possibility of mass manufacture in a relatively short time, and reducing excessive adverse immune responses which, may pose safety problems. In this review, the latest research of DNA vaccine that is designed for intranasal administration are discussed in details.
Title: Analytical challenges and regulatory requirements for nasal drug products in Europe and the US
Author: Prof. Dr. Hartwig Steckel
Abstract: The intranasal route offers great opportunities for both local and systemic administration of drugs and represents an attractive alternative to the oral or intravenous route. Nasal drug delivery can be assessed by a variety of means and regulatory agencies, e.g., FDA and EMA, have published a set of guidelines and regulations proposing in vitro test methods for the characterization of nasal drug products. However, methodologies and details on how to conduct the studies are often missing.This article gives an overview of tests methods required by the FDA and EMA regarding the characterization of nasal drug products and will highlight analogies and differences between the guidelines. Additionally, analytical challenges in the characterization of solution nasal sprays will be reviewed and supported by results from our own studies. These comprise i.a. the determination of droplet size distribution and shot weights and focus on the identification of possible method-, device- and formulation-dependant influencing factors.
Title: Potential Application of Inhalation Drug Delivery to Lung Cancer Treatment
Author: Sunday Shoyele
Affiliation: Department of Pharmaceutical Sciences, School of Pharmarcy, Thomas Jefferson University, Philadelphia, PA
Abstract: Lung cancer is the leading cause of cancer deaths worldwide with a 5-year survival rate of less than 15% for all stages combined. Despite some recent advances in drug discovery, toxicity still remains an issue in the treatment of this highly debilitating disease. Toxicity of most anticancer agents is often attributed to unexpected uptake of such agents by normal tissues and organs. Although, lung cancer is most often a metastatic disease, local delivery of therapeutic agents to the lung by inhalation could potentially act as an additional weapon in the growing arsenal of strategies against lung cancer. In this timely review, we take a critical look at how inhalation as a delivery strategy could be applied to lung cancer treatment. A comprehensive analysis of different factors such as particle design, devices, challenges and early breakthrough is undertaken.
Keywords: lung cancer; inhalation, particle design, drug delivery, toxicity; drug targeting
Last update: 24 October 2013